Herceptin is known to bind to HER2 expressed on breast and ovarian cancer cells causing cytotoxicity in vivo by inhibiting HER2-mediated intracellular signalling, increasing HER2 endocytosis and stimulating antibody-directed cell cytotoxicity (ADCC) (Collins et al., 2012; Kute et al., 2012; Yoshida et al., 2012). Here, ERBB2 is linked to ovarian cancer.